|Arcturus Therapeutics Ltd.|
|Registration Date||11 May 2020|
|Revision Date||11 May 2020|
Medicine PharmaceuticalsCOVID-19 vaccine
Arcturus Therapeutics has announced the development of a Coronavirus (COVID-19) vaccine for Singapore based on the Company’s STARR™ Technology and will take advantage of a unique platform developed at Duke-NUS allowing rapid screening of vaccines for effectiveness and safety.
The STARR™ Technology platform combines self-replicating RNA with LUNAR®, a leading nanoparticle non-viral delivery system, to produce proteins inside the human body. Due to superior immune response and sustained protein expression, Arcturus’ STARR™ Technology is expected to produce a vaccine response at much lower doses compared to traditional mRNA vaccines. This could lead to the ability to treat many more people with a single GMP-manufactured production batch, thereby greatly increasing efficiency and reducing time required to produce sufficient quantities of vaccine for large populations.
It has been observed that STARR™ Technology in pre-clinical models to be effective at extraordinarily low doses -- greater than 30-fold more efficient than traditional mRNA. The Arcturus manufacturing process has been applied in multiple large GMP batches of highly pure RNA in our LUNAR-OTC program. If successful, Arcturus could develop a vaccine capable of vaccinating millions of people for a fraction of the cost of traditional mRNA vaccines.
COVID-19 belongs to a family of coronaviruses that can cause serious respiratory disease. Arcturus plans to apply its STARR™ Technology toward the development of a vaccine to protect against COVID-19. The self-replicating RNA-based therapeutic vaccine triggers rapid and prolonged antigen expression within host cells resulting in protective immunity against infectious pathogens.
In the preclinical evaluation/regulatory stage